Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProtAffin, a biotechnology company developing a new class of biopharmaceutical products that act by targeting cell-surface glycan structures, has entered into manufacturing agreement with CMC Biologics’ Danish operations, located in Copenhagen, Denmark.
Subscribe to our email newsletter
Under the agreement, ProtAffin and CMC’s Danish operations will manufacture PA401 for the treatment of chronic obstructive pulmonary disease (COPD).
Additinally, the agreement covers manufacture and supply of PA401 for preclinical development and early clinical development in COPD and related respiratory indications.
ProtAffin said that PA401 is a glycan-binding decoy protein based on human chemokine IL-8 (CXCL8), which has shown anti-inflammatory activity in both chronic and acute preclinical models of lung inflammation. A composition of matter patent covering PA401 has been granted in the US and the EU.
Andreas Kungl, CSO of ProtAffin, said: “We are delighted to be working with CMC Biologics as our manufacturing partner for our first preclinical product PA401.
“Initiating manufacturing of PA401 to support preclinical and early clinical development of PA401 is a major milestone for ProtAffin.”
David Kauffmann, chairman of CMC Biologics, said: “It is exciting to start working with ProtAffin’s management and science team.”